Naltrexone Pill — Competitive Intelligence Brief

Naltrexone Pill (Naltrexone Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid receptor antagonist. Area: Psychiatry / Addiction Medicine.

marketed Opioid receptor antagonist Opioid receptors (mu, delta, kappa) Psychiatry / Addiction Medicine Small molecule

Target snapshot

Naltrexone Pill (Naltrexone Pill) — Albert Einstein Healthcare Network. Naltrexone is an opioid receptor antagonist that blocks the effects of opioids and reduces cravings for alcohol and opioids.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naltrexone Pill TARGET	Naltrexone Pill	Albert Einstein Healthcare Network	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
MOVANTIK™ (naloxegol)	MOVANTIK™ (naloxegol)	Massachusetts General Hospital	marketed	Peripheral opioid receptor antagonist	Mu-opioid receptor (peripheral)
Methylnaltrexone (MNTX)	Methylnaltrexone (MNTX)	Bausch Health Americas, Inc.	marketed	Peripheral mu-opioid receptor antagonist	Mu-opioid receptor (peripheral)
naltrexone (Revia)	naltrexone (Revia)	University of North Carolina, Chapel Hill	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)
XR-NTX 380 mg, intramuscular injection	XR-NTX 380 mg, intramuscular injection	University of Pennsylvania	marketed	Opioid receptor antagonist	Mu opioid receptor (primary); delta and kappa opioid receptors
Naltrexone Tablet and Placebo Patch	Naltrexone Tablet and Placebo Patch	The Scripps Research Institute	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
long-lasting injectable naltrexone	long-lasting injectable naltrexone	State University of New York - Upstate Medical University	marketed	Opioid receptor antagonist	Opioid receptors (mu, delta, kappa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid receptor antagonist class)

1. Albert Einstein Healthcare Network · 1 drug in this class
2. Cephalon · 1 drug in this class
3. Leiden University Medical Center · 1 drug in this class
4. New York State Psychiatric Institute · 1 drug in this class
5. Paion UK Ltd. · 1 drug in this class
6. Pocket Naloxone Corp · 1 drug in this class
7. State University of New York - Upstate Medical University · 1 drug in this class
8. Texas Tech University · 1 drug in this class
9. The Scripps Research Institute · 1 drug in this class
10. University of North Carolina, Chapel Hill · 1 drug in this class